AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

AI-generated analysis

📈 AbbVie is identified as the smarter dividend buy over Pfizer due to a superior track record of dividend growth and revenue expansion.

💰 AbbVie has increased its quarterly dividend for 53 consecutive years, earning Dividend King status, with a recent 5.5% raise to $1.73 per share.

📉 Pfizer faces greater exposure to patent exclusivity loss between 2026 and 2028, risking roughly $17 billion to $18 billion in annual revenue from core blockbusters.

💊 AbbVie successfully replaced Humira revenue with home-grown assets Skyrizi and Rinvoq, which combined generated over $25 billion in sales by 2025.

📊 Q2 earnings showed AbbVie sales rising 10.2% year over year to $16.9 billion, driven primarily by its immunology portfolio.

💸 Pfizer's debt-to-equity level is more than three times that of AbbVie, creating greater pressure on cash-flow conversion as legacy drugs lose market share.

🤝 AbbVie is executing a multi-year portfolio pivot with recent acquisitions like Apogee Therapeutics ($10.9 billion) to capture new therapeutic areas.

📈 Over the past decade, AbbVie's revenue grew by more than 138% compared to Pfizer's growth of just over 18%.

Bullish Signals
  • AbbVie has increased its quarterly dividend for 53 consecutive years, achieving Dividend King status with a recent 5.5% raise to $1.73 per share.
  • The company successfully navigated the Humira patent cliff by developing Skyrizi and Rinvoq, which combined generated over $25 billion in annual sales by 2025.
  • Second-quarter sales reached $16.9 billion, a 10.2% year-over-year increase driven by strong performance from its immunology drugs.
  • AbbVie returned to mid- to high-single-digit top-line growth after bridging the immunology drop-off without taking a permanent structural hit.
  • The company acquired Apogee Therapeutics for $10.9 billion to gain access to promising atopic dermatitis therapy zumilokibart.
Risk Factors
  • AbbVie carries more long-term debt, roughly $62 billion as of the second quarter, compared to Pfizer's $32.6 billion.
Full Analysis
The article argues that AbbVie (NYSE: ABBV) is the superior dividend investment compared to Pfizer, citing a longer history of dividend growth and stronger revenue expansion. While Pfizer offers a higher current yield at 6.1%, AbbVie provides a more sustainable profile with a Dividend King status, having increased its quarterly dividend for 53 consecutive years. AbbVie successfully navigated the expiration of its blockbuster drug Humira by pivoting to home-grown immunology assets, Skyrizi and Rinvoq. By 2025, these new drugs generated over $25 billion in combined annual sales, effectively replacing lost revenue and pushing total company revenue to record highs. This strategic transition allowed the company to return to mid- to high-single-digit top-line growth without a permanent structural hit. In contrast, Pfizer faces significant patent cliffs between 2026 and 2028, exposing roughly $17 billion to $18 billion in annual revenue from core blockbusters like Eliquis and Ibrance. Although AbbVie carries more total debt at roughly $62 billion, its leverage is manageable due to strong cash flows from new products, whereas Pfizer's debt-to-equity ratio is over three times higher as it pays down obligations amidst legacy drug erosion. Financial performance highlights include AbbVie's second-quarter sales of $16.9 billion, up 10.2% year over year, driven by Skyrizi ($5.5 billion) and Rinvoq ($2.52 billion). The company also recently acquired Apogee Therapeutics for $10.9 billion to expand its atopic dermatitis portfolio, further solidifying its growth trajectory against Pfizer's acquisition of Metsera for weight-loss therapies.